The management of stage IIIA non-small cell lung cancer (NSCLC) is evolving in the era of immune checkpoint inhibitor therapy. In the past, there has been a great deal of controversy regarding the optimal management of patients with N2 nodal metastasis at the time of diagnosis of NSCLC. There are some new questions to address when considering the results of the Checkmate 816 and the NADIM II clinical trials which demonstrated improved disease-free survival and overall survival with neoadjuvant combined chemotherapy and Nivolumab. In addition, what is the role for perioperative radiation in resectable stage IIIA NSCLC in patients who receive neoadjuvant immunotherapy? In this webinar, the moderators and an interdisciplinary panel from major cancer centers across the country discuss the current management of resectable stage IIIA NSCLC in the era of immune checkpoint inhibitor therapy. Panelists: David P. Carbone, MD, PhD​, Jessica Donington, MD​, MSCR (moderator), Nathaniel R. Evans III, MD (moderator), Robert E. Merritt, MD​, and Maria Werner-Wasik, MD